Skin Lesions and Treatment With Tumor Necrosis Factor Alpha Antagonists

Reumatol Clin. 2013;09:53-61 - Vol. 09 Num.01 DOI: 10.1016/j.reumae.2012.07.008

Maria Victoria Hernández^a,, Melina Meineri^a, Raimon Sanmartí<sup>a

a</sup> Unidad de Artritis, Hospital Clínic, Universidad de Barcelona, Barcelona, Spain

Keywords

Dermatological reactions. Skin. Infliximab. Etanercept. Adalimumab.

Abstract

The efficacy shown by biological therapy with tumor necrosis factor (TNF) antagonists has led in the recent years to its increased and extended use in different inflammatory arthropathies. Initially, safety studies of these drugs were mainly focused on the risk of infection and the development of malignancies. Recently, several cases of skin lesions induced by anti-TNF drugs have been reported with an increased incidence, highlighting the importance of the skin as a major target of the side effects of these drugs. In addition to skin lesions directly related to drug administration there is a wide spectrum of skin lesions of different morphology and etiology, especially the development of cutaneous immune-mediated conditions, an emergent phenomenon associated with this treatment. We describe the main skin lesions associated with treatment with anti-TNF drugs according to an extensive review of the literature.

Tools

•  Léalo en Español
•  PDF
•  Print
•  Send
•  Export Citation (RIS format)
•  Download article images